Joan E. Humphreys

4.1k total citations · 1 hit paper
35 papers, 3.2k citations indexed

About

Joan E. Humphreys is a scholar working on Oncology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Joan E. Humphreys has authored 35 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 11 papers in Molecular Biology and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Joan E. Humphreys's work include Drug Transport and Resistance Mechanisms (17 papers), Pharmacological Effects and Toxicity Studies (8 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Joan E. Humphreys is often cited by papers focused on Drug Transport and Resistance Mechanisms (17 papers), Pharmacological Effects and Toxicity Studies (8 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Joan E. Humphreys collaborates with scholars based in United States, United Kingdom and Netherlands. Joan E. Humphreys's co-authors include Joseph W. Polli, Lindsey O. Webster, Stephen A. Wring, Cosette J. Serabjit‐Singh, James P. Morgan, Lili Huang, Kimberly K. Adkison, Kelly A. Harmon, Kenneth R. Brouwer and J. L. Moriarty and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Joan E. Humphreys

35 papers receiving 3.0k citations

Hit Papers

Rational Use of in Vitro P-glycoprotein Assays in Drug Di... 2001 2026 2009 2017 2001 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rational Use of in Vitro P-glycoprotein Assays in Drug Discovery
    2001 545 citations Joseph W. Polli, Stephen A. Wring et al. Journal of Pharmacology and Experimental Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joan E. Humphreys United States 26 1.8k 889 747 582 442 35 3.2k
Rolf W. Sparidans Netherlands 35 2.0k 1.1× 397 0.4× 1.6k 2.1× 364 0.6× 426 1.0× 169 4.2k
Joseph W. Polli United States 38 3.0k 1.7× 1.5k 1.7× 1.4k 1.8× 820 1.4× 985 2.2× 78 5.2k
Jeffrey A. Silverman United States 35 2.0k 1.1× 856 1.0× 1.1k 1.5× 264 0.5× 619 1.4× 93 3.8k
James M. Gallo United States 42 1.3k 0.7× 329 0.4× 1.9k 2.5× 348 0.6× 343 0.8× 154 5.0k
William F. Elmquist United States 49 3.3k 1.9× 1.3k 1.5× 2.2k 3.0× 391 0.7× 270 0.6× 145 7.0k
Gondi Kumar United States 24 894 0.5× 269 0.3× 788 1.1× 826 1.4× 654 1.5× 53 2.5k
Danièle Ouellet United States 31 1.3k 0.7× 322 0.4× 1.4k 1.9× 221 0.4× 318 0.7× 93 3.3k
Gareth J. Veal United Kingdom 32 1.0k 0.6× 615 0.7× 1.3k 1.8× 391 0.7× 244 0.6× 136 3.7k
Timothy W. Synold United States 39 2.3k 1.3× 555 0.6× 2.4k 3.3× 216 0.4× 582 1.3× 194 5.9k
Tycho Heimbach United States 28 618 0.3× 393 0.4× 1.1k 1.4× 236 0.4× 613 1.4× 70 3.4k

Countries citing papers authored by Joan E. Humphreys

Since Specialization
Citations

This map shows the geographic impact of Joan E. Humphreys's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan E. Humphreys with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan E. Humphreys more than expected).

Fields of papers citing papers by Joan E. Humphreys

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan E. Humphreys. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan E. Humphreys. The network helps show where Joan E. Humphreys may publish in the future.

Co-authorship network of co-authors of Joan E. Humphreys

This figure shows the co-authorship network connecting the top 25 collaborators of Joan E. Humphreys. A scholar is included among the top collaborators of Joan E. Humphreys based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan E. Humphreys. Joan E. Humphreys is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reese, Melinda J., Gary D. Bowers, Joan E. Humphreys, et al.. (2015). Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam. Xenobiotica. 46(5). 445–456. 42 indexed citations
2.
Reese, Melinda J., Paul Savina, Grant T. Generaux, et al.. (2012). In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor. Drug Metabolism and Disposition. 41(2). 353–361. 212 indexed citations
3.
Adkison, Kimberly K., Soniya Vaidya, Daniel Y. Lee, et al.. (2009). Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration. Journal of Pharmaceutical Sciences. 99(2). 1046–1062. 36 indexed citations
4.
Polli, Joseph W., Joan E. Humphreys, Kelly A. Harmon, et al.. (2008). The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions. Drug Metabolism and Disposition. 36(4). 695–701. 196 indexed citations
5.
Zamek‐Gliszczynski, Maciej J., Keith Hoffmaster, Joan E. Humphreys, et al.. (2006). Differential Involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in Biliary Excretion of 4-Methylumbelliferyl Glucuronide and Sulfate in the Rat. Journal of Pharmacology and Experimental Therapeutics. 319(1). 459–467. 65 indexed citations
6.
Rautio, Jarkko, Joan E. Humphreys, Lindsey O. Webster, et al.. (2006). IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES. Drug Metabolism and Disposition. 34(5). 786–792. 222 indexed citations
7.
Zamek‐Gliszczynski, Maciej J., Keith Hoffmaster, Xianbin Tian, et al.. (2005). MULTIPLE MECHANISMS ARE INVOLVED IN THE BILIARY EXCRETION OF ACETAMINOPHEN SULFATE IN THE RAT: ROLE OF MRP2 AND BCRP1. Drug Metabolism and Disposition. 33(8). 1158–1165. 54 indexed citations
8.
Gombar, Vijay K., et al.. (2004). Predicting P-glycoprotein substrates by a quantitative structure–activity relationship model. Journal of Pharmaceutical Sciences. 93(4). 957–968. 77 indexed citations
9.
10.
Polli, Joseph W., Todd M. Baughman, Joan E. Humphreys, et al.. (2004). THE SYSTEMIC EXPOSURE OF AN N-METHYL-d-ASPARTATE RECEPTOR ANTAGONIST IS LIMITED IN MICE BY THE P-GLYCOPROTEIN AND BREAST CANCER RESISTANCE PROTEIN EFFLUX TRANSPORTERS. Drug Metabolism and Disposition. 32(7). 722–726. 20 indexed citations
11.
Humphreys, Joan E.. (2004). The Iraq Dossier and the Meaning of Spin. Parliamentary Affairs. 58(1). 156–170. 12 indexed citations
12.
Polli, Joseph W., et al.. (2003). P‐glycoprotein Influences the Brain Concentrations of Cetirizine (Zyrtec®), a Second‐Generation Non‐Sedating Antihistamine. Journal of Pharmaceutical Sciences. 92(10). 2082–2089. 68 indexed citations
13.
Humphreys, Joan E., Lindsey O. Webster, Stephen A. Wring, et al.. (2002). Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs. Journal of Pharmacology and Experimental Therapeutics. 303(3). 1029–1037. 458 indexed citations
14.
Lentz, Kimberley A., Joseph W. Polli, Stephen A. Wring, Joan E. Humphreys, & James E. Polli. (2000). Influence of Passive Permeability on Apparent P-glycoprotein Kinetics. Pharmaceutical Research. 17(12). 1456–1460. 105 indexed citations
15.
Polli, Joseph W., et al.. (1999). Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor. Pharmaceutical Research. 16(8). 1206–1212. 185 indexed citations
16.
Smith, Gary K., Todd A. Blumenkopf, Michael Cory, et al.. (1997). Toward Antibody-directed Enzyme Prodrug Therapy with the T268G Mutant of Human Carboxypeptidase A1 and Novel in VivoStable Prodrugs of Methotrexate. Journal of Biological Chemistry. 272(25). 15804–15816. 42 indexed citations
17.
Pendergast, William, Scott H. Dickerson, I K Dev, et al.. (1993). Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some 3-amino- and 3-methylbenzo[f]quinazolin-1(2H)-ones. Journal of Medicinal Chemistry. 36(16). 2279–2291. 45 indexed citations
18.
Sculpher, Mark, Brian Ferguson, Joan E. Humphreys, et al.. (1991). Screening for Treatable Diabetic Retinopathy: a Comparison of Different Methods. Diabetic Medicine. 8(4). 371–377. 109 indexed citations
19.
Sculpher, Mark, Brian Ferguson, Joan E. Humphreys, et al.. (1991). A Relative Cost‐effectiveness Analysis of Different Methods of Screening for Diabetic Retinopathy. Diabetic Medicine. 8(7). 644–650. 39 indexed citations
20.
Humphreys, Joan E. & Marion Waite. (1989). ALPHA-1 BLOCKERS. A NEW GENERATION OF ANTIHYPERTENSIVE AGENTS. Journal of Clinical Pharmacy and Therapeutics. 14(4). 263–283. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rolf W. Sparidans Breakdown of academic impact, for papers by Joseph W. Polli Breakdown of academic impact, for papers by Jeffrey A. Silverman Breakdown of academic impact, for papers by James M. Gallo Breakdown of academic impact, for papers by William F. Elmquist Breakdown of academic impact, for papers by Gondi Kumar Breakdown of academic impact, for papers by Danièle Ouellet Breakdown of academic impact, for papers by Gareth J. Veal Breakdown of academic impact, for papers by Timothy W. Synold Breakdown of academic impact, for papers by Tycho Heimbach
Rankless by CCL
2026